April 20, 2011 -- The LinkMed Board of Directors proposes to the Annual General Meeting to be convened
on May 10 to change the name of the company from LinkMed AB to Allenex AB. All
Swedish transplantation companies in the transplantation group will move to new
common production and office facilities in Kungsholmen, Stockholm. Olerup SSP and
AbSorber have already moved to the new premises and the parent company will follow in
early May.
The strategic decision made in September 2010, to focus the future business on the
transplantation field has led to a need to create a new common identity and a unified brand for
the businesses in this area. The LinkMed Board of Directors therefore proposes to the Annual
General Meeting May 10, 2011 to change its corporate name from LinkMed AB to Allenex AB for
its future transplantation business.
"The change of name to Allenex is an important step in further clarifying our new strategic focus
on transplantation. The name Allenex has clear links to genetics (alleles) and transplantation
(TX)," says Ingemar Lagerlof the CEO of LinkMed.
Olerup SSP and AbSorber are subsidiaries of LinkMed and part of the LinkMed Group. The
Group also includes the U.S. sales company Olerup Inc.LinkMed AB will be the first company in
the group to change name to Allenex.
For more information please contact:
Ingemar Lagerlöf, CEO LinkMed: +46 8 508 939 393
Okee Williams, Portfolio Manager LinkMed: +46 8 508 939 40
Or visit
LinkMed AB discloses the information provided herein pursuant to the Securities Markets Act
and/or the Financial Instruments Trading Act. The information was submitted for publication at
14:45 (CET) on April 19, 2011.
LinkMed has two business areas, a commercial transplantation sector business with two
subsidiaries and a venture portfolio comprising life science companies. The venture companies,
all of which are associated companies, consist of four companies in drug development and
biotechnology and six companies in diagnostics and medical technology. LinkMed is listed on
NASDAQ OMX Stockholm, Small Cap sector (ticker symbol: LMED).
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.